Followers
0
Following
0
Blog Posts
0
Threads
84
Blogs
Threads
Portfolio
Follower
Following
2022-03-26 23:14 | Report Abuse
Hibiscus have 11.68% in 3D oil and 3D oil have a 100% interest in WA-527-P exploration
licence
2022-03-12 14:07 | Report Abuse
this TDM if sell goreng pisang tepi jalan also will rugi,i remember before they had A&W also can rugi and sell away
2022-03-04 14:23 | Report Abuse
trying to do a meme stock?
2022-02-22 21:51 | Report Abuse
Dnex might have some palm oil tree around Silterra factory fence
2022-02-21 22:13 | Report Abuse
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3209149
Sorry, this is the correct one, earlier one was about PP price fixing
2022-02-21 21:52 | Report Abuse
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3206386
We refer to the earlier announcements dated 28 July 2020, 12 August 2020, 13 August 2020, 18 August 2020, 20 October 2020, 28 October 2020, 30 October 2020, 12 November 2020, 23 November 2020, 24 November 2020, 21 January 2021, 4 February 2021, 5 February 2021, 9 February 2021, 11 February 2021, 15 February 2021, 16 February 2021, 12 March 2021, 18 March 2021, 19 March 2021, 30 July 2021,13 August 2021, 2 November 2021 and 12 November 2021 in relation to the Private Placement.
On behalf of the Board, UOBKH wishes to announce that 64,577,280 Placement Shares were listed and quoted on the Main Market of Bursa Malaysia Securities Berhad with effect from 9.00 a.m. on 15 November 2021, which marks the completion of the Private Placement.
This announcement is dated 15 November 2021.
2022-02-21 21:52 | Report Abuse
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3206386
On behalf of the Board, UOBKH wishes to announce that the Board had on 2 November 2021 resolved to fix the issue price for the Private Placement at RM0.6948 per Placement Share.
The issue price of RM0.6948 per Placement Share represents a discount of approximately 9.99% to the 5-day VWAP of DNeX Shares up to and including 1 November 2021, being the last traded day of DNeX Shares immediately preceding the price-fixing date of RM0.7719 per DNeX Shares.
2021-01-05 19:27 | Report Abuse
2021-01-05 14:17 | Report Abuse
Selling very well https://www.apotec.com.my/Home/ProductInfo?ProductID=47
2021-01-03 00:45 | Report Abuse
there is a high chance of K Power getting job from these successful bidders
2021-01-02 21:03 | Report Abuse
same main ingredient as herbal medicine cleared for covid-19 in Thailand but in a tea bags
https://www.apotec.com.my/Home/ProductInfo?ProductID=47
2021-01-01 00:02 | Report Abuse
Conversion or selling conditions (Vesting)
Generally, employee stock subscription rights will have some conditions to prevent a large amount of selling pressure, which means that it will attach conditions that the subscribed stocks will not be sold or converted until a period of time in the future, or that it can be sold or sold in the next few years on average. Convert a few percent. This additional condition depends on the individual company.
2020-12-30 14:59 | Report Abuse
Andrographis Paniculata,,hempudu bumi is commercially planted by Bioalpha
2020-12-19 00:46 | Report Abuse
PROPOSED DIVERSIFICATION OF THE EXISTING BUSINESS OF NOTION VTEC
BERHAD AND ITS SUBSIDIARIES TO INCLUDE THE PRODUCTION AND TRADING
OF GLOVES (“PROPOSED DIVERSIFICATION”)
2020-12-19 00:29 | Report Abuse
Exercise Price : Exercise price of the Warrants C at RM0.75 for every 1 new Homeritz
Share. Upon implementation of the Proposed Bonus Issue of Shares,
the exercise price of the Warrants C will be adjusted to RM0.60
2020-12-13 22:49 | Report Abuse
possible, if the government suddenly says that they will buy a Chinese vaccine through Bio(PNB is a majority shareholder)
2020-12-12 00:08 | Report Abuse
since the Australian Gov is still not interested in it(Covax-19), probably because it's still at stage 2 and if it gets past stg 3 successfully then this MOU to manufacture it here will be something big.
2020-10-22 14:12 | Report Abuse
New first quarter is from June to August,bought Focus Dynamics from 6-10th July and K Star on 15th Sept(2nd Q)
2020-10-22 13:02 | Report Abuse
quarter should be reporting some paper gain for purchase of Focus and proceeds from PP
2020-10-21 21:57 | Report Abuse
Quarter report should be next week
2020-09-26 22:05 | Report Abuse
We refer to the Company’s announcements dated 6 May 2020, 12 May 2020 and 16 June 2020 respectively
pertaining to the manufacturing of Nasal Swabs for use in COVID-19 testing by 3D printing.
The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes
to announce that the Company’s wholly owned subsidiary, K-One Resources Sdn. Bhd. (“K-One Res”) has,
on 3 September 2020, received the approval from the Medical Device Authority of Malaysia (MDA) for the
supply of Nasal Swab in Malaysia by local manufacturing. The mass production is in place. The K-One Group
has been preparing the marketing network and is in position to activate the target customers locally either
directly and/or through distributors.
In addition, the K-One Group is continuing to reach out to targeted overseas markets that have potential high
demand for Nasal Swabs due to running escalating COVID-19 infections or second wave infections
2020-09-26 21:57 | Report Abuse
Covid-19 Medical Aids
Following the outbreak of Covid-19, K-One has taken the initiative to expand its medical/healthcare portfolio to include medical aids such as nasal swabs and ventilators to assist frontliners in the combat against Covid-19. The above said product range expansion was initiated to spur growth in its existing medical/healthcare business and at the same time it enables K-One to conduct its corporate social responsibility role by manufacturing cost effective and vital medical devices to meet market demands during such times of unprecedented crisis.
These ventilators which are manufactured under license from NASA-JPL and the nasal swabs are subjected to approval by the designated authorities in the respective countries which they are to be sold. K-One shall work with selected distributors on a non-exclusive basis to market the above medical devices in the identified countries.
If you are currently in the medical/healthcare distribution business and interested to add on the above vital medical devices in your supply list, please touch base with us at corp@k-one.com.
Stock: [SCICOM]: SCICOM (MSC) BHD
2023-06-22 09:49 | Report Abuse
https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=226500&name=EA_DS_ATTACHMENTS
Scicom mentioned page 7